




Product Introduction

Lopinavir

Lopinavir is a potent **HIV protease** inhibitor with K_i of 1.3 pM.

Technical Data:

Molecular Weight (MW):	628.8	
Formula:	C ₃₇ H ₄₈ N ₄ O ₅	
Solubility (25°C)	DMSO 126 mg/mL	
* <1 mg/ml means slightly soluble or insoluble:	Water <1 mg/mL	
	Ethanol 126 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder 6 months-80°C in DMSO	
CAS No.:	192725-17-0	

Biological Activity

Lopinavir binds to mutant HIV protease (V82A, V82F and V82T) with K_i of 4.9 pM, 3.7 pM and 3.6 pM, respectively. Lopinavir inhibits 93% of wild-type HIV protease activity at 0.5 nM. Lopinavir inhibits HIV protease activity in the absence and presence of 50% HS with EC_{50} of 17 nM and 102 nM, respectively, in MT4 cells. ^[1] Lopinavir is converted to several metabolites in an NADPH-dependent manner in liver microsomes with the primary metabolites M-3 and M-4. ^[2] Lopinavir is a potent inhibitor of Rh123 efflux in Caco-2 monolayers with IC_{50} of 1.7 mM. Lopinavir exposure (72 hours) in LS 180V cells reduces the content of intracellular Rh123. Lopinavir induces P-glycoprotein immunoreactive protein and messenger RNA levels in LS 180V cells. ^[3] Lopinavir inhibits subtype C clone C6 with IC_{50} of 9.4 nM. ^[4] Lopinavir inhibits CYP3A with IC_{50} of 7.3 mM in human liver microsomes, while produces negligible or weak inhibition of human CYP1A2, 2B6, 2C9, 2C19 and 2D6. ^[5]

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Lopinavir (10 mg/kg, orally) results in C_{max} of 0.8 µg/mL and oral bioavailability of 25% in rats. ^[1]

References

- [1] Sham HL, et al. *Antimicrob Agents Chemother*, 1998, 42(12), 3218-3224.
- [2] Kumar GN, et al. *Drug Metab Dispos*, 1999, 27(1), 86-91.
- [3] Vishnuvardhan D, et al. *AIDS*, 2003, 17(7), 1092-1094.
- [4] Gonzalez LM, et al. *Antimicrob Agents Chemother*, 2003, 47(9), 2817-2822.
- [5] Weemhoff JL, et al. *J Pharm Pharmacol*, 2003, 55(3), 381-386.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.